Company intelligence / Profile preview

DecodeCell

Reykjavík, Icelandpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~500
Development stage: Preclinical

Overview

deCODE has discovered key genetic risk factors for dozens of common diseases and has published numerous studies in major scientific journals. Recent discoveries include a rare missense variant in FRS3 associated with decreased BMI and protection against obesity, and rare loss-of-function variants in HECTD2 and AKAP11 associated with bipolar disorder.

Therapeutic areas: OncologyPsychiatryCardiovascularEndocrinology
Modalities: GeneticsGenomics
Industry: Drug Discovery Services

Partnerships

RocheMerckBayerWyeth

Beyond the preview

Go deeper on DecodeCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DecodeCell.

Explore the full profile